| scholarly article | Q13442814 |
| P2093 | author name string | Atsushi Nishikawa | |
| Hiroyuki Enomoto | |||
| Masanori Taketsuna | |||
| Fumito Yoshiki | |||
| Kenta Kajimoto | |||
| P2860 | cites work | Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. | Q50852375 |
| Renal function and risk of hip and vertebral fractures in older women. | Q51924728 | ||
| Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. | Q51932388 | ||
| Association of kidney function with incident hip fracture in older adults. | Q53245136 | ||
| Epidemiology of osteoporosis in Japan. | Q53619512 | ||
| Relationship between moderate to severe kidney disease and hip fracture in the United States | Q79150009 | ||
| Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis | Q81730772 | ||
| K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
| Challenges in implementing and maintaining osteoporosis therapy | Q34073740 | ||
| Diagnostic criteria for primary osteoporosis: year 2000 revision | Q34422528 | ||
| Treatment for Osteoporosis among Women in Japan: Associations with Patient Characteristics and Patient-Reported Outcomes in the 2008-2011 Japan National Health and Wellness Surveys | Q34837665 | ||
| Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). | Q35892694 | ||
| Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. | Q36071882 | ||
| Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary | Q36454522 | ||
| An estimate of the worldwide prevalence and disability associated with osteoporotic fractures | Q36597363 | ||
| Lifetime incidence of CKD stages 3-5 in the United States | Q37045873 | ||
| Teriparatide in the management of osteoporosis | Q37068993 | ||
| Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report | Q37082771 | ||
| Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis | Q37950740 | ||
| Osteoporosis and treatments in Japan: management for preventing subsequent fractures | Q38093784 | ||
| Therapy for patients with CKD and low bone mineral density | Q38150099 | ||
| Bone disease in CKD: a focus on osteoporosis diagnosis and management | Q38204098 | ||
| Revised equations for estimated GFR from serum creatinine in Japan | Q39513402 | ||
| Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label ph | Q42665480 | ||
| Prevalence of low femoral bone density in older U.S. adults from NHANES III. | Q44113237 | ||
| Prevalence of chronic kidney disease in the Japanese general population. | Q45975235 | ||
| In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures | Q46525769 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | 1653-1659 | |
| P577 | publication date | 2016-11-15 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study | |
| P478 | volume | 11 |
| Q90450534 | Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q47701411 | Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). |
| Q92138236 | Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk |
Search more.